Mesoblast Limited
MESOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. With a market capitalization of $2.13B, it sits in mid-cap territory. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Market Cap
$2.13B
Beta
0.82
P/E (TTM)
—
P/E (Fwd)
36.02
EPS (TTM)
$-0.44
EPS (Fwd)
$0.46
ROE
-9.9%
ROA
-4.1%
Cash
$102.9M
Total Debt
$127.3M
Free CF
-$52.0M
52W Change
15.5%
Annual Financials
Cash vs Debt
Where MESO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MESO finished 11.48% above its 150-day moving average ($15.51) and 7.46% above its 200-day moving average ($16.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MESO overbought or oversold?
At the September 3, 2026 close, MESO's RSI(14) was 54.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $102.9M in cash, though total debt stands at $127.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$52.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -9.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $7.5M (2023) to $120.2M (2026), reflecting a 1503% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MESO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.